GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
=== Toxicology === PFOA is a possible carcinogen, a possible liver toxicant, a possible developmental toxicant, and a possible immune system toxicant, and also exerts hormonal effects including alteration of thyroid hormone levels at very high concentrations. Animal studies show developmental toxicity from reduced birth size, physical developmental delays, endocrine disruption, and neonatal mortality. PFOA alters lipid metabolism. In 2008, PFOA has been described as a member of a group of "classic non-genotoxic carcinogens". However, a provisional German assessment notes that a 2005 study found PFOA to be genotoxic via a peroxisome proliferation pathway that produced oxygen radicals in HepG2 cells, and a 2006 study demonstrated the induction and suppression of a broad range of genes; therefore, it states that the indirect genotoxic (and thus carcinogenic) potential of PFOA cannot be dismissed. As of November 2023, the International Agency for Research on Cancer (IARC) has classified PFOA as carcinogenic to humans (Group 1) based on "sufficient" evidence for cancer in animals and "strong" mechanistic evidence in exposed humans. An additional study has shown PFOA to be developmentally toxic, hepatotoxic, immunotoxic, and to have negative effects of thyroid hormone production.
Wes Moore became the 63rd governor of Maryland on January 18, 2023. A member of the Democratic Party, he defeated far-right state delegate Dan Cox in the 2022 Maryland gubernatorial election by a margin of 32%, becoming the state's first African-American governor. Moore has generally governed as a moderate. During his first term, he supported removing regulations limiting new housing development, restarted efforts to build the Red Line, and supported the implementation of the Blueprint for Maryland's Future. He also backed efforts to establish a service year option for high school graduates, improve abortion access and public safety, and decrease child poverty in Maryland. Moore engaged in recovery efforts after the Francis Scott Key Bridge collapse, and oversaw the passage of a tax reform bill in 2025.
=== Centers for Disease Control and Prevention (CDC) === The CDC focuses on the analysis, research, and technical assistance within the CLIA partnership. In particular, the CDC establishes technical standards and guidelines, conducting studies, monitoring practices, and developing resources. In addition, the CDC manages the Clinical Laboratory Improvement Advisory Committee (CLIAC). CLIAC is made up of experts in many specialties throughout clinical and anatomic pathology that provide guidance and advice on general issues within laboratory science. The CDC specifically acknowledges that point-of-care testing simply describes the location at which the testing is performed and not the complexity of the test itself. With technological innovation, more complex tests will be able to be performed at the bedside that may not be CLIA-waived like some other at-home point of care tests that the FDA has waived such as urine dipsticks.
== Sources and bioavailability == Naringenin and its glycoside has been found in a variety of herbs and fruits, including grapefruit, oranges, and lemons, sour orange, sour cherries, tomatoes, cocoa, Greek oregano, water mint, as well as in beans. Ratios of naringenin to naringin vary among sources, as do enantiomeric ratios. The naringenin-7-glucoside form seems less bioavailable than the aglycol form. Grapefruit juice can provide much higher plasma concentrations of naringenin than orange juice. Naringenin can be absorbed from cooked tomato paste. There are 3.8 mg of naringenin in 150 grams of tomato paste.
==== Rituximab ==== Rituximab is a chimeric monoclonal IgG1 antibody specific for CD20, developed from its parent antibody Ibritumomab. As with ibritumomab, rituximab targets CD20, making it effective in treating certain B-cell malignancies. These include aggressive and indolent lymphomas such as diffuse large B-cell lymphoma and follicular lymphoma and leukemias such as B-cell chronic lymphocytic leukemia. Although the function of CD20 is relatively unknown, CD20 may be a calcium channel involved in B-cell activation. The antibody's mode of action is primarily through the induction of ADCC and complement-mediated cytotoxicity. Other mechanisms include apoptosis and cellular growth arrest. Rituximab also increases the sensitivity of cancerous B-cells to chemotherapy.
Sources: en.wikipedia.org
==== Mount Koya ==== It was developed by Mokujiki Shonin, a Shingon priest in the early 1600s during the Edo Period. He encouraged all the mountain temples to make their own tofu after he obtained large amounts of soybeans from the head Shingon temple. The purpose of this was to preserve some of the frozen tofu until the Spring equinox. Firm tofu was left outdoors in the cold windy night to freeze. After it was frozen, it was allowed to stand on shelves in a shed for fifteen days at temperatures below freezing, thawed in warm water and pressed lightly to expel the melted ice, then dried in the shed using heat from charcoal braziers.
This suggested that it was evolutionarily more difficult to increase the UV-sensitivity of the eyes of the males than to increase the UV-signals emitted by the females. Many insects use the ultraviolet wavelength emissions from celestial objects as references for flight navigation. A local ultraviolet emitter will normally disrupt the navigation process and will eventually attract the flying insect.
== Biological control of nematodes == This fungus has been investigated as a biocontrol agent of agriculturally important nematodes, most notably those responsible for gastrointestinal infection of grazing animals. These parasitic infections are commonly treated with anthelmintic agents including benimidazole, levamisole and invermectin. However, increasing levels of anthelmintic resistance have been observed, driving the search for new treatment and prevention options. Larvae of animal-pathogenic nematodes are found in soil. The prospect of treating contaminated soils with nematode pathogenic fungi such as H. anguillulae has shown potential to reduce nematode populations. However, the fungus does not persist in soil following the elimination of nematode populations, potentially limiting its use as a sustainable biocontrol agent.
== Diagnosis == Blood tests for the diagnosis of diabetic ketoacidosis measure glycemia (sugar level), pH (blood acidity), and ketone bodies. As urgent medical treatment is often required when DKA is suspected, the tentative diagnosis can be made based on clinical history and by calculating the anion gap from the basic metabolic panel, which would demonstrate a high anion-gap metabolic acidosis along with high glucose levels. This allows timely treatment with fluids and insulin well before direct serum ketone body testing results arrive. Urine ketone testing is also available but this cannot easily distinguish DKA from other causes of ketonuria without more context. Diagnostic workup should also include tests to determine any potential infectious trigger for DKA such as pneumonia or UTI.
=== Nuclear stress test === Adenosine is used as an adjunct to thallium (Tl-201) or technetium (Tc-99m) myocardial perfusion scintigraphy (nuclear stress test) in patients unable to undergo adequate stress testing with exercise.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.